image
Intra-Cellular Therapies, Inc. ITCI
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 83.42
-4.8 %
$ 8.84 B
Market Cap
-100.51
P/E
INCOME STATEMENT
464 M REVENUE
86.40%
Growth Rates
1Year 86.40%
3Years 174.18%
5Years 0.00%
7Years 181.60%
10Years 67.09%
-159 M OPERATING INCOME
39.54%
Growth Rates
1Year 39.54%
3Years 11.67%
5Years 0.36%
7Years -4.36%
10Years -19.76%
-140 M NET INCOME
45.49%
Growth Rates
1Year 45.49%
3Years 14.95%
5Years 2.08%
7Years -2.63%
10Years -17.92%
EFFICIENCY
Earnings Waterfall Intra-Cellular Therapies, Inc.
image
Revenue 464 M
Cost Of Revenue 33.7 M
Gross Profit 431 M
Operating Expenses 590 M
Operating Income -159 M
Other Expenses -19.7 M
Net Income -140 M

Income Statement

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015 Dec-2014 Dec-2013 Mar-2013
REVENUE
Revenue 464.4 249.1 81.7 22.5 60.6 K 0 0.2 0.3 91.4 K 0.6 2.7 3.1
GROSS PROFIT
Cost Of Revenue 33.7 20.4 8.0 1.9 0.5 0.4 79.4 93.8 0.1 21.2 23.0 15.5
Gross Profit 430.6 228.7 73.7 20.6 (0.4) (0.4) (79.2) (93.5) 48.3 K (20.6) (20.3) (12.4)
OPERATING INCOME
Operating Expenses 590.0 492.3 359.4 251.9 154.1 162.3 103.1 118.6 105.9 31.6 29.0 19.5
Selling, General and Administrative Expenses 409.9 358.8 272.6 186.4 64.9 30.1 23.7 24.8 18.2 10.3 6.0 4.0
Research and Development Expenses 180.1 134.7 88.8 65.8 89.1 132.2 79.4 93.8 87.7 21.2 23.0 15.5
Operating Income (159.4) (263.6) (285.7) (231.2) (154.0) (162.3) (102.8) (118.3) (105.8) (31.0) (26.3) (16.4)
PRE-TAX INCOME
Interest Income Expense 0 7.4 0 0 0 0 0 36.8 K 0 7.07 K 0.6 0.2
Total Other Income 20.3 7.4 1.6 4.2 6.3 7.1 4.0 2.9 1.0 0.3 (0.6) (0.2)
Pre-Tax Income (139.0) (256.2) (284.1) (227.0) (147.7) (155.1) (98.8) (115.4) (104.8) (30.7) (26.9) (16.6)
NET INCOME
Tax Provision 0.6 6 K 5.63 K 13.5 K 1.6 K 1.6 K (1.1) 1.1 1.6 K 1.6 K 18 K 32.9 K
Net Income (139.7) (256.3) (284.1) (227.0) (147.7) (155.1) (97.8) (116.4) (104.8) (30.7) (26.9) (16.6)
EPS 1.46 2.72 3.5 3.23 2.68 2.84 2.12 2.69 2.91 1.07 1.56 0.75